Co‐morbidities in heart failure beginning to sprout—and no end in sight?

Haehling, Stephan von

doi:10.1002/ejhf.1098

Cited by 15 publications

(9 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…21, 22 Depending on the cancer diagnosis and the type of anti-cancer treatment, cardiotoxicity rates may vary from 0% to 48% of patients, with HF being a predominant presentation. 27 HF is characterized by multiple symptoms such as reduced physical performance, 28 shortness of breath, 29 fluid retention, 30 general weakness 31 , and prolonged hospital stays 32 , which ultimately also result into substantial healthcare costs. 27 HF is characterized by multiple symptoms such as reduced physical performance, 28 shortness of breath, 29 fluid retention, 30 general weakness 31 , and prolonged hospital stays 32 , which ultimately also result into substantial healthcare costs.…”

Section: Introductionmentioning

confidence: 99%

“…23 HF is associated with a 5-year survival rate of nearly 50% [24][25][26] and is frequently accompanied by reduced quality of life. 27 HF is characterized by multiple symptoms such as reduced physical performance, 28 shortness of breath, 29 fluid retention, 30 general weakness 31 , and prolonged hospital stays 32 , which ultimately also result into substantial healthcare costs. 33 Besides HF, other frequent cardiovascular (CV) problems associated with anti-cancer therapies include coronary artery disease, 34 atrial fibrillation, 35 arterial hypertension, 36 thromboembolic disease 37 , valvular disease 38 , pulmonary hypertension, 39 stroke, 40 and peripheral vascular disease.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

et al. 2019

View full text Add to dashboard Cite

While anti-cancer therapies, including chemotherapy, immunotherapy, radiotherapy, and targeted therapy, are constantly advancing, cardiovascular toxicity has become a major challenge for cardiologists and oncologists. This has led to an increasing demand of cardio-oncology units in Europe and a growing interest of clinicians and researchers. The Heart Failure 2019 meeting of the Heart Failure Association of the European Society of Cardiology in Athens has therefore created a scientific programme that included four dedicated sessions on the topic along with several additional lectures. The major points that were discussed at the congress included the implementation and delivery of a cardio-oncology service, the collaboration among cardio-oncology experts, and the risk stratification, prevention, and early recognition of cardiotoxicity. Furthermore, sessions addressed the numerous different anti-cancer therapies associated with cardiotoxic effects and provided guidance on how to treat cancer patients who develop cardiovascular disease before, during, and after treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In patients with heart failure (HF), prevalence values are much higher and reach values between 19.5% and 47.3% 9 . Moreover, among patients with diabetes mellitus and obesity, sarcopaenia has been described as a common metabolic comorbidity in patients with HF 10 with reduced or preserved ejection fraction, showing a prevalence of almost 20% in both conditions 11 , 12 . Sarcopaenia may be a strong predictor of mortality in patients with HF, but evidence on this is still limited 13 .…”

Section: Introductionmentioning

confidence: 99%

Sarcopaenia complicating heart failure

Fonseca

Haehling

2019

European Heart Journal Supplements

Self Cite

View full text Add to dashboard Cite

Sarcopaenia is defined as reduced skeletal muscle mass associated with either a decline in muscle strength or low physical performance. It has been shown to affect 17.5% of people worldwide, with a prevalence of 20% or higher in patients with heart failure (HF). Sarcopaenia has severe impact on mortality, physical capacity, and quality of life. Even though several mechanisms, such as autonomic imbalance, reduced muscle blood flow, increased inflammation, hormonal alterations, increased apoptosis, and autophagy have been proposed to fuel the pathogenesis of sarcopaenia, additional studies assessing the interaction of these conditions need to be conducted to elucidate how the presence of sarcopaenia can exacerbate the progression of HF and vice-versa. Resistance training combined with nutritional protein intake seems to be effective in the treatment of sarcopaenia, although current pharmacotherapies have not been extensively studied with this endpoint in mind. In conclusion, sarcopaenia is interwoven with HF and leads to worse exercise capacity in these patients. The mechanisms associated with this bilateral relationship between sarcopaenia and HF are still to be elucidated, leading to effective treatment, not only for the heart, but also for the skeletal muscle.

show abstract

“…Further studies regarding the contribution of these comorbidities in mortality still need to be developed. 20 Learning about disparate socioeconomic conditions that modify the incidence of HF in different regions in the same country can also be derived from population registries. Even in health systems such as that of the UK, it can be seen that social inequalities interfere with accessibility and lead to a consequent increase in cases of the syndrome.…”

mentioning

confidence: 99%